European survey showed wide variations in diagnostic procedures and management strategies for metabolic bone disease of prematurity in 22 countries

Abstract

AbstractAimThe aim of this study was to evaluate the clinical relevance, diagnostic procedures and treatment strategies for metabolic bone disease in preterm infants across Europe.MethodsAn e‐survey was distributed by email to 545 neonatal units in 38 European countries between July and October 2021. The protocol was based on the Checklist for Reporting Results of Internet E‐Surveys.ResultsIn total, 76 neonatal units (14%) from 22 European countries (58%) completed the e‐survey. In the 12 months prior to the survey, 29% of 76 units reported at least one symptomatic case of fracture associated with metabolic bone disease of prematurity, and 18% of 76 units reported at least one case of craniofacial deformity. Most centres followed local guidelines for diagnosis (77% of 73 units) and treatment (63% of 72 units). Alkaline phosphatase was the blood marker most used for treatment indication (81% of 72 units), and phosphate supplementation was the treatment most used (82% of 71 units).ConclusionMetabolic bone disease of prematurity remains clinically relevant. Wide variations in diagnostic procedures and management strategies were observed in European neonatal units. Evidence‐based consensus guidelines appear urgently needed to reduce the number of symptomatic cases.